Sam Morovati Named Vice President of Sales at Delta-Q Technologies
8.1.2020 17:00:00 EET | Business Wire | Press release
Delta-Q Technologies (Delta-Q) today announced that sales veteran Sam Morovati has joined the company as vice president of sales, responsible for leading Delta-Q’s global sales channels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005218/en/
Sam Morovati will oversee global sales growth and customer satisfaction for Delta-Q Technologies (Photo: Business Wire)
“As Delta-Q continues to pursue growth within the global battery charger and broader technology markets, we are excited to welcome Sam to our team,” said Sarah MacKinnon, chief financial officer and executive vice president of Delta-Q. “Sam is a seasoned and results-driven leader in the technology sector, and we are confident his leadership will support Delta-Q’s and our customers’ missions.
He has a proven track record and offers tremendous leadership, mentoring and coaching skills, which will be valuable assets for us going forward. We are counting on him to ensure that our strategic sales plans will firmly align with our corporate vision, mission and values.”
Morovati has more than two decades of sales, marketing and technology management services expertise. He brings significant skillsets to his new post, including experience driving the go-to market strategies with enterprise operating in the telecommunications, enterprise software, automation, renewable energy, smart-grid, industrial control, and industrial Internet of Things. He will lend that expertise to propel Delta-Q into new markets and industries.
Prior to joining Delta-Q, Morovati served as sales director at Honeywell, in Toronto, helping its Ontario customers optimize operations with Honeywell security, building automation, software and services. He also spent six years at Schneider Electric as a Territory sales manager, and national business developer for the wind renewable market. Sam earned his electrical and electronics engineering degree from Bogazici University in Istanbul, Turkey and his Master of Business Administration in Management of Technology from Simon Fraser University in Vancouver, BC.
“I am excited to be a part of Delta-Q’s dynamic team,” said Morovati. “Delta-Q is powering the global adoption of battery-powered technologies and I look forward to strengthening their position in electrification market. I am eager to work closely with our global sales team, customers and partners to help them achieve their objectives and contribute to a greener world for our future.”
About Delta-Q Technologies
Delta-Q Technologies develops and supplies battery chargers to original equipment manufacturers (OEMs) of electric vehicles and industrial equipment. Delta-Q’s unique blend of engineering capability in high efficiency power electronics and embedded software design delivers innovative battery charging solutions to meet the evolving needs of its customers. With more than a million vehicles and industrial machines already using its products, Delta-Q’s innovation is enabling the widespread adoption of environmentally friendly electric drive systems. Delta-Q was founded in 1999 and is a privately held company located in Vancouver, Canada. Please visit www.delta-q.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005218/en/
Contact information
Amanda Yeo, Delta-Q Technologies
Marketing Manager
marketing@delta-q.com
AnnMarie Henriksson, Communiqué PR
Phone: (206) 282-4923 ext. 119
Email: Delta-Q@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom